Want to see IOVA full AI Analyst Report?
IOVA Stock Chart & Stats
$8.44
-$0.14(-2.73%)
At close: 4:00 PM EDT
$8.44
-$0.14(-2.73%)
Day’s Range― - ―
52-Week Range$1.76 - $10.98
Previous CloseN/A
Volume9.43M
Average Volume (3M)14.79M
Market Cap
$4.62B
Enterprise Value$1.62K
Total Cash (Recent Filing)$297.67M
Total Debt (Recent Filing)$46.00M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 05, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding452,971,440
10 Day Avg. Volume14,330,764
30 Day Avg. Volume14,791,526
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.43Price Target Upside11.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$412.17M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRapidly accelerating revenue indicates growing adoption of AMTAGVI and expanding commercial execution. Sustained patient treatment growth can improve operating leverage, support investment in manufacturing and trials, and establish a stronger recurring foundation for future revenue expansion.
Gross Margin ExpansionThe sharp improvement in gross margin suggests that manufacturing scale and operating efficiency are beginning to strengthen the economics of the commercial platform. If maintained as volume grows, higher margins can accelerate the path toward profitability and improve internal funding capacity.
Commercial InfrastructureA growing authorized treatment center network expands patient access and creates infrastructure for higher treatment volumes. Broad geographic coverage, combined with increasing provider experience, can make AMTAGVI easier to deliver and support durable commercial penetration in melanoma and future indications.
Bears Say
Persistent LossesPersistent operating and net losses show that the commercial platform has not yet established a sustainable earnings base. Although losses are narrowing, continued negative margins can limit reinvestment flexibility and leave profitability dependent on further volume growth and cost discipline.
Negative Cash FlowOngoing negative cash generation means growth is not yet self-funding and requires continued improvement in operating performance or access to external capital. Cash burn also increases execution sensitivity as Iovance funds commercial expansion, registrational trials, and next-generation programs.
Pipeline Evidence RiskThe encouraging response rates in additional indications are based on very small patient cohorts, limiting statistical confidence and predictability. Larger studies must confirm durability and efficacy before these programs can materially broaden the addressable market or diversify dependence on AMTAGVI.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $1.76 and its highest was $10.98 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $4.62B.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 43 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Aug 06, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.023.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.09.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 452,971,440 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went up 43.088%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in IOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.43 (11.71% Upside)
$9.43 (11.71% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 96%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 45.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
401.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
IOVA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and meaningful operational progress: record revenue ($99.3M), a best-ever 56% gross margin, accelerating Amtagvi uptake (~$91M revenue, +51% sequential and +68% YoY), expanding ATC footprint (>95 ATCs), and important pipeline/regulatory milestones (LUN-202 near-complete enrollment, SARATOGA Fast Track). Key challenges include limited sample sizes in some early efficacy readouts, pending international reimbursement/approvals, near-term guidance review, and the need to sustain funding for continued scale and trials. On balance, the positive commercial momentum, margin expansion, pipeline advancement, and disciplined cost management significantly outweigh the near-term uncertainties.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$9.43
▲(11.71% Upside)
Technical Analysis
Nektar Therapeutics
―
Arcus Biosciences
―
Immatics
―
Nuvation Bio
―
Immunocore Holdings
―
Ownership Overview
0.34% Insiders
12.09% Mutual Funds
14.92% Other Institutional Investors
54.53% Public Companies and Individual Investors